Targeting KRAS Diversity: Covalent Modulation of G12X and Beyond in Cancer Therapy

targeting informed the design of molecules addressing other mutations, often in a covalent manner. These findings offer promise for innovative approaches in addressing commonly occurring KRAS mutations such as G12D, G12V, G12A, G12S, and G12R in various cancers.